KCT0008552尚未招募Unknown
A Prospective, Open-label, Pragmatic Randomized Control Trial to Demonstrate the Effect of Improving the Venous Reflux Time by Vitis Vinifera Seed Extract in Patients with Varicose Vein of Lower Extremity
Yonsei University Yongin Severance Hospital0 个研究点目标入组 200 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 80(Year)（—）
- 性别
- All
入选标准
- •1) Adult men and women between the ages of 19 and under 80
- •2) Patients who meet the results of venous Doppler ultrasonography
- •- In case of valvular regurgitation for 0.5 seconds or longer in superficial veins (great saphenous vein, small saphenous vein, etc.)
- •- In case of valvular regurgitation for more than 1 second in deep veins (popliteal veins, etc.)
- •3) Completed the washout period as below, including the screening period, up to visit 2
- •- Analgesics, steroids, anti-inflammatory drugs, venoactive (such as Enteron) drugs: 4 weeks or more
- •4) Patients who voluntarily consent in writing to participate in this clinical trial
排除标准
- •1) Patients with peripheral vasoocclusive arterial disease of the lower extremities
- •2) Patients with asymptomatic varicose veins
- •3) Subjects diagnosed with acute deep vein thrombosis
- •4) People with frequent leg pain due to neuropathy
- •5) Patients or prospective patients undergoing varicose vein surgery/surgical procedure(However, patients who have undergone surgery or surgical procedure for more than 1 year from the time of screening can participate in the study)
- •6) Subjects who diagnosed with systemic diseases that cause edema or thrombosis, such as: Heart failure, endocrine disorders (hypothyroidism, Cushing's syndrome, uncontrolled diabetes), allergic reactions to other drugs, urticaria and angioedema, malabsorption and protein-calorie malnutrition, obstructive sleep apnea Diseases determined by the examiner to be associated with edema or thrombosis due to thrombosis, etc.
- •7) Those who have malignant tumor within 5 years from the time of screening. (However, in the following cases, it is possible to participate in clinical trials.)
- •(1) If you have the ability within 5 years from the time of screening, but you maintain a cured state without recurrence or metastasis
- •(2) At least 5 years after completion of tumor treatment based on time of screening or if disease-free
- •(3) At least 1 year after successful treatment for complete resection of basal cell/squamous cell carcinoma, radical resection of papillary thyroid carcinoma, or cervical carcinoma in situ based on screening time point
- •8) Subjects with severe new functional impairment (serum creatinine value = 2 times the upper limit of normal of the testing laboratory) based on the time of screening
- •9) Subjects with severe hepatic dysfunction (ALT or AST levels =3 times the laboratory's upper limit of normalization) based on the time of screening
- •10) Subjects who should receive diuretics or contraindicated drugs and contraindicated therapies that may affect the results of this clinical trial during the clinical trial period
- •11) Those who have been diagnosed with clinically significant mental illness, alcohol abuse, etc.
- •12) Persons with a history of hypersensitivity reactions to clinical trial drugs or ingredients of this drug
- •13) Persons with a history of hypersensitivity reactions to clinical trial drugs or ingredients of this drug
- •14) people who are pregnant or breastfeeding
- •15) Women of childbearing potential who plan to become pregnant during the study period
- •16) Subjects who are determined to be inappropriate for clinical trial participation by the investigator's judgment
研究者
相似试验
已完成
2 期
A clinical study to evaluate efficacy and safety of Seven Different Topical Formulations in Subjects Suffering from Osteoarthritis of Knee(s)CTRI/2012/05/002672Emami Limited210
尚未招募
不适用
Efficacy and safety of Levonadifloxacin versus Teicoplanin-Azithromycin combination in hospitalized patients with Community Acquired Bacterial Pneumonia (CABP)CTRI/2022/05/042613Dr Anand Nikalje
尚未招募
4 期
To assess the efficacy and safety of a probiotic product (Streptococcus salivarius K12) in children with recurrent upper respiratory tract infection.CTRI/2024/01/061611Dr Reddy’s Laboratories Ltd
尚未招募
不适用
EEfficacy and safety of Levonadifloxacin with Teicoplanin-Aztreonam combination in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI) including diabetic foot infectioCTRI/2022/06/043031Dr Anand Nikalje
已完成
3 期
Desvenlafaxine succinate ER tablet in the Management of Major Depressive DisorderCTRI/2009/091/000129Emcure Pharmaceuticals Limited Pune